Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ABN202

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Abion, Genopharm

Drug class:

EGFR inhibitor, IFN stimulant, TROP-2 inhibitor

Related drugs:

‹

human interferon alpha 2b (1)

alpha-interferon (0)

TROP2-CAR-NK (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

BAY 2927088 (1)

Compound 6a (1)

abivertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

human interferon alpha 2b (1)

alpha-interferon (0)

TROP2-CAR-NK (0)

›

Urothelial Cancer

Sensitive: D – Preclinical

Sensitive: D – Preclinical